Please assess the completion status of the following clinical trial:

Trial Title: Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meet all inclusion criteria for the AIBL study protocol, with amyloid PET conducted or planned and MRI available~* Subjects in the MCI and AD groups required to have a reliable caregiver capable of providing information about the subjects' symptoms~Exclusion Criteria:~* lifetime history of schizophrenia, schizoaffective disorder, or bipolar disorder~* history of electroconvulsive therapy~* MRI contraindicated~* claustrophobic or, otherwise, unable to tolerate the imaging procedure~* current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram~* history of additional risk factors for Torsades de Pointes~* current clinically significant infectious disease, endocrine or metabolic disease, or pulmonary, renal, or hepatic impairment that the investigator believes would affect study participation~* history of cancer (other than skin or in situ prostate cancer) within the previous 5 years~* current drug or alcohol abuse/dependence~* history of alcohol abuse/dependence with 2 years of the onset of the symptoms of dementia~* females of childbearing potential who were not surgically sterile, not refraining from sexual activity, or not using reliable methods of contraception

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Alzheimer's disease (AD) (Type: EXPERIMENTAL): Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
- Mild cognitive impairment (MCI) (Type: EXPERIMENTAL): Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
- Subjective memory complainers (SMC) (Type: EXPERIMENTAL): Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
- Cognitively normal (CN) (Type: EXPERIMENTAL): Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).